Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy

To conduct a multicenter case series characterizing the clinical characteristics at presentation and pancreatic volume changes of patients with checkpoint inhibitor-associated autoimmune diabetes (CIADM). Electronic medical records were reviewed with 36 consecutive patients identified with CIADM, as...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2024-04, Vol.109 (5), p.1301-1307
Main Authors: Wu, Linda, Carlino, Matteo Salvatore, Brown, David Alexander, Long, Georgina Venetia, Clifton-Bligh, Roderick, Mellor, Rhiannon, Moore, Krystal, Sasson, Sarah Christina, Menzies, Alexander Maxwell, Tsang, Venessa, Gunton, Jenny Elizabeth
Format: Article
Language:English
Subjects:
Atrophy - chemically induced
Autoantibodies
C-Peptide
Diabetes Mellitus, Type 1 - chemically induced
Diabetes Mellitus, Type 1 - drug therapy
Diabetic Ketoacidosis
Humans
Lipase
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To conduct a multicenter case series characterizing the clinical characteristics at presentation and pancreatic volume changes of patients with checkpoint inhibitor-associated autoimmune diabetes (CIADM). Electronic medical records were reviewed with 36 consecutive patients identified with CIADM, as defined by (1) previous immune checkpoint inhibitor (ICI) therapy, (2) new-onset hyperglycemia (blood glucose level ≥ 11.1 mmol/L and/or glycosylated hemoglobin ≥ 6.5%), and (3) insulin deficiency [C-peptide
ISSN:0021-972X
1945-7197
1945-7197
DOI:10.1210/clinem/dgad685